CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 0.5%

CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report)'s stock price shot up 0.5% on Wednesday . The stock traded as high as $57.78 and last traded at $56.72. 278,122 shares traded hands during mid-day trading, a decline of 85% from the average session volume of 1,806,296 shares. The stock had previously closed at $56.41.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Needham & Company LLC reissued a "buy" rating and issued a $90.00 price objective on shares of CRISPR Therapeutics in a research report on Thursday, April 11th. Royal Bank of Canada increased their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a "sector perform" rating in a report on Thursday, February 22nd. Morgan Stanley boosted their price target on CRISPR Therapeutics from $46.00 to $48.00 and gave the company an "underweight" rating in a research note on Monday, February 26th. Wells Fargo & Company raised their price target on shares of CRISPR Therapeutics from $55.00 to $70.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 22nd. Finally, Mizuho boosted their price objective on shares of CRISPR Therapeutics from $82.00 to $99.00 and gave the company a "buy" rating in a report on Wednesday, March 6th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of "Hold" and an average target price of $76.29.

CRISPR Therapeutics Stock Performance

The firm's fifty day simple moving average is $71.75 and its 200-day simple moving average is $63.80. The stock has a market cap of $4.72 billion, a P/E ratio of -28.39 and a beta of 1.76.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Wednesday, February 21st. The company reported $1.10 EPS for the quarter, beating the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to the consensus estimate of $148.72 million. The firm's revenue for the quarter was up 3253.3% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.41) EPS. Analysts predict that CRISPR Therapeutics AG will post -6.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 19,582 shares of the company's stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares of the company's stock, valued at $12,468,589.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, General Counsel James R. Kasinger sold 2,801 shares of the firm's stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the transaction, the general counsel now directly owns 60,070 shares of the company's stock, valued at $4,701,078.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Samarth Kulkarni sold 19,582 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $59.91, for a total transaction of $1,173,157.62. Following the completion of the sale, the chief executive officer now owns 208,122 shares of the company's stock, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 133,992 shares of company stock valued at $9,157,835. 4.10% of the stock is owned by company insiders.

Institutional Trading of CRISPR Therapeutics

A number of hedge funds have recently bought and sold shares of the business. CWM LLC grew its stake in CRISPR Therapeutics by 80.7% in the 3rd quarter. CWM LLC now owns 582 shares of the company's stock valued at $26,000 after buying an additional 260 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in CRISPR Therapeutics by 545.5% in the third quarter. Tradewinds Capital Management LLC now owns 710 shares of the company's stock valued at $32,000 after purchasing an additional 600 shares in the last quarter. Blue Trust Inc. purchased a new position in CRISPR Therapeutics in the 4th quarter worth approximately $32,000. Headlands Technologies LLC purchased a new stake in shares of CRISPR Therapeutics during the 3rd quarter valued at $34,000. Finally, Bourgeon Capital Management LLC lifted its stake in CRISPR Therapeutics by 1,000.0% during the fourth quarter. Bourgeon Capital Management LLC now owns 550 shares of the company's stock worth $34,000 after purchasing an additional 500 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.